# Merck & Co., Inc., Rahway, NJ, USA (United States)

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/merck-and-co-inc-rahway-nj-usa-united-states/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 49 |
| Citations | 7,698,843 |
| City | Rahway |
| Country | US |
| Description | Merck & Co., Inc., Rahway, NJ, USA (United States) is a research organisation in Rahway, US. OpenAlex records 37,054 works and 7,698,843 citations for it. 11,161 researchers list it as their most recent affiliation. |
| Homepage | https://www.merck.com |
| OpenAlex ID | https://openalex.org/I1285764155 |
| Region | New Jersey |
| Researchers | 11,161 |
| ROR ID | https://ror.org/02891sr49 |
| Type | company |
| Works | 37,054 |

## University collaborators

Showing 10 of 19.

- [Institut Gustave Roussy](https://scholariq.org/institutions/institut-gustave-roussy/)
- [University of California, Los Angeles](https://scholariq.org/institutions/university-of-california-los-angeles/)
- [Sidney Kimmel Comprehensive Cancer Center](https://scholariq.org/institutions/sidney-kimmel-comprehensive-cancer-center/)
- [Memorial Sloan Kettering Cancer Center](https://scholariq.org/institutions/memorial-sloan-kettering-cancer-center/)
- [Dana-Farber Cancer Institute](https://scholariq.org/institutions/dana-farber-cancer-institute/)
- [The University of Texas MD Anderson Cancer Center](https://scholariq.org/institutions/the-university-of-texas-md-anderson-cancer-center/)
- [Princess Margaret Cancer Centre](https://scholariq.org/institutions/princess-margaret-cancer-centre/)
- [University of Chicago](https://scholariq.org/institutions/university-of-chicago/)
- [Angeles Clinic and Research Institute](https://scholariq.org/institutions/angeles-clinic-and-research-institute/)
- [University of California, San Francisco](https://scholariq.org/institutions/university-of-california-san-francisco/)

## University papers

Showing 12 of 129.

- [Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer](https://scholariq.org/papers/pembrolizumab-versus-chemotherapy-for-pd-l1-positive-non-small-cell-lung-cancer/)
- [PD-1 Blockade in Tumors with Mismatch-Repair Deficiency](https://scholariq.org/papers/pd-1-blockade-in-tumors-with-mismatch-repair-deficiency/)
- [Integrated genomic analyses of ovarian carcinoma](https://scholariq.org/papers/integrated-genomic-analyses-of-ovarian-carcinoma/)
- [Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer](https://scholariq.org/papers/mutational-landscape-determines-sensitivity-to-pd-1-blockade-in-non-small-cell/)
- [Comprehensive genomic characterization defines human glioblastoma genes and core pathways](https://scholariq.org/papers/comprehensive-genomic-characterization-defines-human-glioblastoma-genes-and-core/)
- [Heart Disease and Stroke Statistics—2012 Update](https://scholariq.org/papers/heart-disease-and-stroke-statistics-2012-update/)
- [Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade](https://scholariq.org/papers/mismatch-repair-deficiency-predicts-response-of-solid-tumors-to-pd-1-blockade/)
- [Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer](https://scholariq.org/papers/pembrolizumab-plus-chemotherapy-in-metastatic-non-small-cell-lung-cancer/)
- [Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial](https://scholariq.org/papers/pembrolizumab-versus-docetaxel-for-previously-treated-pd-l1-positive-advanced/)
- [Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer](https://scholariq.org/papers/pembrolizumab-for-the-treatment-of-non-small-cell-lung-cancer/)
- [Heart Disease and Stroke Statistics—2011 Update](https://scholariq.org/papers/heart-disease-and-stroke-statistics-2011-update/)
- [Heart Disease and Stroke Statistics—2014 Update](https://scholariq.org/papers/heart-disease-and-stroke-statistics-2014-update/)

## University researchers

- [Jaime Mejia](https://scholariq.org/researchers/jaime-mejia/)
- [Kim M. Hirshfield](https://scholariq.org/researchers/kim-m-hirshfield/)
- [Kerry T. Blanchard](https://scholariq.org/researchers/kerry-t-blanchard/)
- [Talia Boulanger](https://scholariq.org/researchers/talia-boulanger/)

## University top topics

Showing 8 of 25.

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Chemical Synthesis and Analysis](https://scholariq.org/topics/chemical-synthesis-and-analysis/)
- [Analytical Chemistry and Chromatography](https://scholariq.org/topics/analytical-chemistry-and-chromatography/)
- [Receptor Mechanisms and Signaling](https://scholariq.org/topics/receptor-mechanisms-and-signaling/)
- [HIV/AIDS drug development and treatment](https://scholariq.org/topics/hiv-aids-drug-development-and-treatment/)
- [Monoclonal and Polyclonal Antibodies Research](https://scholariq.org/topics/monoclonal-and-polyclonal-antibodies-research/)
- [Health Systems, Economic Evaluations, Quality of Life](https://scholariq.org/topics/health-systems-economic-evaluations-quality-of-life/)
- [Computational Drug Discovery Methods](https://scholariq.org/topics/computational-drug-discovery-methods/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.